Screener
Vertex Pharmaceuticals VRTX Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $1.1B+6.5% | $1.03B+59.6% | $1.19B— | $1.08B+3.6% | $1.03B+129% | ||
| —— | $55.9M+15.5% | $55.7M+19.8% | $54M+1.5% | $51.7M-4.3% | ||
| —— | $166.4M+0.2% | $157.6M-6.1% | $194.9M+5.6% | $167.3M+8.5% | ||
| —— | $1.43B+74.4% | $498M+504% | $1.24B+1,108% | $1.07B+129% | ||
| —— | $133.4M+228% | $149.4M+61.3% | $101.8M+50.4% | $145.7M+111% | ||
| —— | -$431.9M-674% | -$288.1M+64.9% | -$117M+66.4% | -$484.5M-4.5% | ||
| —— | $336.9M-20.9% | $128.4M-69.3% | $1.07B+248% | $391.8M+22.3% | ||
| —— | -$538.8M+20.8% | -$77.2M+80.3% | -$1.15B-198% | -$349.2M+2.6% | ||
| —— | $417.1M+268% | $140M+121% | $0— | $296.6M+106% |
FAQ
- Where does Vertex Pharmaceuticals's cash flow data come from?
- Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
